单剂人乳头瘤病毒(HPV)疫苗能否预防宫颈癌?印度研究的早期发现
在印度开展的多中心整群随机试验中,未婚10-18岁女孩按实际接种剂次分为四组,随访免疫原性与HPV感染。单剂四价HPV疫苗对HPV 16和18型可产生稳健且持续4年的免疫应答,抗体水平低于三剂和两剂但稳定;随访至7年时,各接种组HPV 16和18型感染频率相似且均低,未接种对照妇女显著更高。单剂保护效果与两剂和三剂相似,但制定单剂政策指南前仍需7年以上长期保护数据。
要点
- 单剂四价HPV疫苗对HPV 16和18型免疫应答稳健且持续4年,抗体水平低于三剂和两剂但稳定。
- 随访至7年,各接种组HPV 16和18型感染频率相似且均低,未接种对照妇女显著更高。
- 单剂保护效果与两剂和三剂相似,但制定单剂政策指南前仍需7年以上长期保护数据。
核心结论
- 单剂四价HPV疫苗具有免疫原性,对HPV 16和18型感染提供的持久保护与三剂和两剂方案相似,但研究存在一些局限性。
- 在制定和实施关于单剂的政策指南之前,需要获得7年以上针对HPV感染和宫颈癌前病变的长期保护数据。
- 单剂显著且持久的保护效果可成为许多低收入国家引入单剂HPV疫苗的有力论据,这些国家目前宫颈癌预防的标准是「不干预」。
研究设计与样本
- 在印度开展的多中心整群随机试验,比较四价HPV疫苗(Gardasil™)两剂与三剂接种。
- 因与本研究无关的事件暂停接种,导致未婚10-18岁女孩按方案部分接种,形成四个研究组,两个按设计、两个按默认。
- 按实际接种剂次数分析,随访主要结局为免疫原性(L1基因型特异性结合抗体滴度、中和抗体滴度、抗体亲和力)和HPV感染。
- 研究注册号:ISRCTN98283094;ClinicalTrials.gov注册号:NCT00923702。
主要发现
- 17729名接种女孩中,4348名(25%)在第1、60、180天或之后接种三剂,4979名(28%)在第1、180天或之后接种两剂,3452名(19%)在第1、60天接种两剂,4950名(28%)接种一剂。
- 单剂接种者对HPV 16和18型表现出稳健且持续的免疫应答,虽低于三剂或两剂接种者,但抗体水平在4年期间保持稳定。
- 随访至7年,累积 incident 和持续性HPV 16和18型感染频率在所有接种组相似且均低;未接种年龄匹配对照妇女的HPV 16和18型感染频率显著高于疫苗接种者。
- 疫苗非靶向HPV型别感染频率在接种组间相似,但在未接种对照妇女中更高。
临床怎么用
- 作者认为,单剂四价HPV疫苗具有免疫原性,对HPV 16和18型感染提供的持久保护与三剂和两剂方案相似。
- 作者指出,在制定和实施关于单剂的政策指南之前,需要获得7年以上针对HPV感染和宫颈癌前病变的长期保护数据。
- 作者认为,单剂显著且持久的保护效果可成为许多低收入国家引入单剂HPV疫苗的有力论据。
局限性
- 原文指出该研究存在一些局限性,但摘要中未具体说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human papillomavirus (HPV) vaccination is a major strategy for preventing cervical and other ano-genital cancers. Worldwide HPV vaccination introduction and coverage will be facilitated if a single dose of vaccine is as effective as two or three doses or demonstrates significant protective effect compared to 'no vaccination'. METHODS: In a multi-centre cluster randomized trial of two vs three doses of quadrivalent HPV vaccination (Gardasil™) in India, suspension of the vaccination due to events unrelated to the study led to per protocol and partial vaccination of unmarried 10-18 year old girls leading to four study groups, two by design and two by default. They were followed up for the primary outcomes of immunogenicity in terms of L1 genotype-specific binding antibody titres, neutralising antibody titres, and antibody avidity for the vaccine-targeted HPV types and HPV infections. Analysis was per actual number of vaccine doses received. This study is registered with ISRCTN, number ISRCTN98283094; and with ClinicalTrials.gov, number NCT00923702. FINDINGS: Of the 17,729 vaccinated girls, 4348 (25%) received three doses on days 1, 60, 180 or later, 4979 (28%) received two doses on days 1 and 180 or later, 3452 (19%) received two doses on days 1 and 60, and 4950 (28%) received one dose. One dose recipients demonstrated a robust and sustained immune response against HPV 16 and 18, albeit inferior to that of 3- or 2-doses and the antibody levels were stable over a 4 year period. The frequencies of cumulative incident and persistent HPV 16 and 18 infections up to 7 years of follow-up were similar and uniformly low in all the vaccinated study groups; the frequency of HPV 16 and 18 infections were significantly higher in unvaccinated age-matched control women than among vaccine recipients. The frequency of vaccine non-targeted HPV types was similar in the vaccinated groups but higher in the unvaccinated control women. CONCLUSION: Our results indicate that a single dose of quadrivalent HPV vaccine is immunogenic and provides lasting protection against HPV 16 and 18 infections similar to the three- and two-dose vaccine schedules, although the study suffer from some limitations. Data on long term protection beyond 7 years against HPV infection and cervical precancerous lesions are needed before policy guidelines regarding a single dose can be formulated and implemented. Significant and long-lasting protective effect of a single dose can be a strong argument to introduce one dose of the HPV vaccine in many low income countries where the current standard of care for cervical cancer prevention is 'no intervention'.
引用
- Sankaranarayanan R, Joshi S, Muwonge R, et al. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. Vaccine. 2018. PMID: 29551226. doi:10.1016/j.vaccine.2018.02.087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。